Dermatology

Guselkumab Treats Axial Disease in Psoriatic Arthritis

Save

Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.

IL-6 Inhibition in Refractory Systemic Sclerosis

Save

A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype. 

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Save

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Risk Factors Associated with Systemic Sclerosis Hospitalization

Save

A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.

Record review of 95 SSc patients from a single-centre cohort seen between 2010 and 2020 found that over half (53

Diagnostic Delay in Half of Psoriatic Arthritis Patients

Save

 A Mayo Clinic/ Olmsted County study of psoriatic arthritis (PsA) patients has shown that more than half (55%) of PsA patients had a diagnostic delay of > 2 years, and that this delay has not improved over time.

A retrospective, population-based cohort examined incident adult PsA

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Save

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors

Save

Today, Sept.1st, the FDA announced its decision regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co.

These safety concerns arise from

TNF Inhibitor Induced IgA Vasculitis in IBD

Save

A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after  or during anti-TNF-α therapy.

A retrospectively analysis of the GETAID and FVSG networks identified, 43 patients

Predictors of Inflammatory Arthritis

Save

Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

Save

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Biologic Therapy of Psoriasis May Prevent Psoriatic Arthritis

Save

Another retrospective cohort study has shown that biologic treatment of psoriasis may reduce the subsequent incidence of psoriatic arthritis (PsA).

Analysis of electronic medical records of a large HMO identfied psoriasis patients who had received treatment for psoriasis (but were

Tocilizumab in Refractory Skin and Joint Scleroderma

Save

The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc)  and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization.

TCZ is currently FDA approved for use in SSc

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

1. 
   

   In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@

Skin Involvement with HMGCR Necrotizing Myositis

Save

The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported.

Anti-3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies have been linked to the immune-mediated

FDA Approves Anifrolumab in SLE

Save

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  

Saphnelo the 

RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)

Save

How much psoriasis do you need to have in order to have psoriatic arthritis? This plus a review of rheumatology and COVID news from the past week on RheumNow.com.

Shingles Risk with JAK Inhibitors and Other Biologics

Save

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.

RA patients from the German RABBIT register were prospectively enrolled (2007 - 2020)